🇺🇸 FDA
Pipeline program

MYCOPHENOLATE MOFETIL, Rilvegostomig, RAMUCIRUMAB, INFLIXIMAB

D6187C00001

Phase 2 small_molecule active

Quick answer

MYCOPHENOLATE MOFETIL, Rilvegostomig, RAMUCIRUMAB, INFLIXIMAB for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials